Immunopharmacology Comments

IL-5 is a major driver of eosinophil growth, differentiation, recruitment, activation, and survival and is considered an important factor in asthma pathogenesis [4]. Mepolizumab-mediated neutralisation of IL-5 activity leads to a reduction in eosinophil numbers in blood, tissue and sputum and this effect underlies the drug's anti-inflammatory action. Nucala® became the first respiratory biologic to be authorised for self-administration [1], following FDA approval of autoinjector and pre-filled safety syringe versions of the drug in June 2019.

Immunopharmacology Disease
Disease	X-Refs	Comment	References
Asthma	Disease Ontology: DOID:2841 OMIM: 600807	Approved therapeutic for severe eosinophilic asthma.
Hypereosinophilic syndrome, idiopathic; HES	OMIM: 607685 Orphanet: ORPHA3260	FDA and EMA orphan therapy for hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis (also known as Churg-Strauss syndrome or allergic granulomatosis).